Mei Ri Jing Ji Xin Wen·2025-12-07 23:05Group 1: Diplomatic Tensions - The Chinese Foreign Ministry responded to Japan's claims of radar illumination by Chinese naval aircraft, asserting that Japan's frequent reconnaissance activities pose a greater risk to maritime security [2][5][6] - China rejected Japan's so-called negotiations and has lodged counter-protests in both Beijing and Tokyo, urging Japan to cease its disruptive actions [2][5][6] Group 2: Pharmaceutical Developments - The 2025 National Medical Insurance Directory has added 114 new drugs, including 50 innovative drugs such as Teriparatide and the domestic ADC drug [7] - The commercial insurance directory now includes five CAR-T cell therapies and two imported Alzheimer's drugs, with CAR-T therapy costing over one million yuan per treatment if paid out of pocket [7] Group 3: Financial Issues in Companies - Xiangyuan Cultural Tourism announced that its actual controller is responsible for the overdue financial products, clarifying that these products are unrelated to the company and it bears no repayment obligations [3][15] - Other companies, including Jiaojian Co. and Haichang Ocean Park, also issued statements regarding the financial product issues [15][16] Group 4: Regulatory Actions - First Capital has received a notice of administrative penalty from the Jiangsu Securities Regulatory Bureau, with potential fines nearing 20 million yuan due to supervisory failures in a past convertible bond project [14] - The rapid investigation and penalty process highlights the increasing regulatory scrutiny in the investment banking sector [14]